Objectives: We report our prospective clinical result of transurethral resection in saline (TURIS) versus monopolar transurethral resection of the prostate (TURP) system in treating large-volume benign prostatic hyperplasia (BPH). Patients and Methods: Patients with BPH (volume >50 ml) were enrolled in the study. An intravenous device was used for serum sodium and hemoglobin tests to monitor the alteration. All acute complications were noted. Patients were followed up for at least 6 months. Results: Forty patients were randomized into two groups. Follow-up data were compared with baseline. The decline in serum sodium postoperatively was smaller in the TURIS group (6.9 ± 0.7 vs. 14.8 ± 1.8 mM, p = 0.001). Hemoglobin only dropped by 1.4 g/dl in the TURIS group, whereas it dropped by 2.5 g/dl in the TURP group (p = 0.001). The TURIS system showed a better resection rate (0.64 vs. 0.52 g/min, p = 0.001). Total acute complication rate was 8 of 19 (42%) in the TURP arm and 4 of 21 (19%) in the TURIS arm. The catheter was removed sooner (2.5 vs. 3.4 days) and hospitalization time was less (3.0 vs. 4.2 days) in the TURIS group. The mean improvement in the International Prostate Symptom Score and maximum urinary flow rate at 6 months was comparable in the two groups. Conclusion: The TURIS system demonstrated superior safety in treating large-volume BPH and had a similar efficacy to TURP in short term.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.